Metopirone (Metyrapone)

Metyrapone inhibits the adrenal enzyme 11‑beta‑hydroxylase, which is essential for the final step of cortisol synthesis. By blocking this enzyme, the drug lowers cortisol levels and triggers a rise in ACTH, useful for both diagnostic and therapeutic purposes.

The dosage of Metopirone is individualized. A qualified prescriber determines the appropriate dose based on the specific indication, patient characteristics, and clinical response. Patients should follow the prescribing information provided by their healthcare professional.

The pregnancy category for metyrapone is unknown. It should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare provider is essential.

To order Metopirone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metopirone differs from alternatives such as ketoconazole or osilodrostat by specifically targeting 11‑beta‑hydroxylase. Ketoconazole has broader enzyme inhibition and may cause more hepatic effects, while osilodrostat also inhibits 11‑beta‑hydroxylase but with a different potency and safety profile. Choice depends on clinical context and physician judgment.

Metopirone tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain stability and potency.

Metopirone is taken orally, usually with a glass of water. The exact timing (e.g., with or without food) and frequency are determined by the prescribing clinician based on the therapeutic goal.

The most serious risks include adrenal insufficiency, which can lead to life‑threatening hypotension, severe hypotension itself, and allergic reactions such as rash or angioedema. Patients should be monitored closely for these events.

Metopirone should be avoided in individuals with known hypersensitivity to metyrapone or any excipients, and in patients with severe hepatic impairment unless specifically directed by a specialist. Caution is also advised for those with uncontrolled cardiovascular disease.